Learning Objectives:

  1. Presentation of new biomarkers (URI and IL-17A) for HCC and its associated metabolic disorders (diabetes and NASH)
  2. Metabolic alterations (NAD+ deficit-induced DNA damage) as key and first events for the development of diabetes, NASH and liver tumorigenesis
  3. Presentation of therapeutic strategies (NAD+ boosters and IL-17A signaling blockers) to prevent diabetes, NASH, and HCC
Session date: 
09/23/2019 - 12:00pm to 1:00pm CDT
900 East 57th Street
KCBD Auditorium 1103
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Professor Nabil Djouder, PhD